Cervical Cancer Screening Positivity Among Women Living With HIV in CDC-PEPFAR Programs 2018–2022

Author:

McCormick Laura J.1ORCID,Gutreuter Steve1,Adeoye Oluwatosin2,Alger Sarah X.3,Amado Celeste4,Bay Zurnaid5,Chirwa Catherine Motswere6,Chituwo Omega7,Correia Della5,Deus Maria5,Dirlikov Emilio3,Efuntoye Tim2,Gunde Laurence8,Kabaghe Alinune8,Kalamya Julius N.3,Lorenzoni Cesaltina4,Magesa Daniel9,Mate Celina4,Mulokoshi Theopolina10,Ninsiima Josephine Connie11,Nyangasi Mary12,Nyika Ponesai13,Pasipamire Munyaradzi14,Ssali Mina15,Tefera Fana16,Torre Lindsey A.1,Urso Marilena5,Wandira Ronald6,Zemburuka Brigitte17,Montandon Michele1

Affiliation:

1. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA;

2. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Abuja, Nigeria;

3. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Kampala, Uganda;

4. National Cervical Cancer Control Program, Ministry of Health, Maputo, Mozambique;

5. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Maputo, Mozambique;

6. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Gaborone, Botswana;

7. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Lusaka, Zambia;

8. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi;

9. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Dar es Salaam, Tanzania;

10. Ministry of Health and Social Services, Windhoek, Namibia;

11. Makerere University School of Public Health, Kampala, Uganda;

12. Division of National Cancer Control Program, Ministry of Health, Nairobi, Kenya;

13. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Harare, Zimbabwe;

14. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Mbabane, Eswatini;

15. Office of the Director of Public Health, Ministry of Health, Kampala, Uganda;

16. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Addis Ababa, Ethiopia; and

17. Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention (CDC), Windhoek, Namibia.

Abstract

Background: The US President's Emergency Plan for AIDS Relief aims to address the higher risk of cervical cancer among women living with HIV by offering high-quality screening services in the highest burden regions of the world. Methods: We analyzed the US President's Emergency Plan for AIDS Relief Monitoring, Evaluation, and Reporting data from Centers for Disease Control and Prevention–supported sites in 13 countries in sub-Saharan Africa for women living with HIV aged older than 15 years who accessed cervical cancer screening services (mostly visual inspection, with ablative or excisional treatment offered for precancerous lesions), April 2018–March 2022. We calculated the positivity by age, country, and clinical visit type (first lifetime screen or routine rescreening). We fitted negative binomial random coefficient models of log-linear trends in time to estimate the probabilities of testing positive and any temporal trends in positivity. Results: Among the 2.8 million completed cancer screens, 5.4% identified precancerous lesions, and 0.8% were positive for suspected invasive cervical cancers (6.1% overall). The positivity rates declined over the study period among those women screening for cervical cancer for the first time and among those women presenting to antiretroviral therapy clinics for routine rescreening. Conclusions: These positivity rates are lower than expectations set by the published literature. Further research is needed to determine whether these lower rates are attributable to the high level of consistent antiretroviral therapy use among these populations, and systematic program monitoring and quality assurance activities are essential to ensure women living with HIV have access to the highest possible quality prevention services.

Funder

Centers for Disease Control and Prevention

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3